The Effect of Safinamide, a Novel Drug for Parkinson's Disease, on Pressor Response to Oral Tyramine: A Randomized, Double-Blind, Clinical Trial

Trial Profile

The Effect of Safinamide, a Novel Drug for Parkinson's Disease, on Pressor Response to Oral Tyramine: A Randomized, Double-Blind, Clinical Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2012

At a glance

  • Drugs Safinamide (Primary) ; Phenelzine; Selegiline
  • Indications Parkinson's disease
  • Focus Pharmacodynamics
  • Acronyms EudraCT2008-000770-21
  • Most Recent Events

    • 01 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top